--- title: "DARK BLUE THERAPEUTICS LTD — Ownership Dossier" canonical: https://whiteintel.dev/entity/25b5159c-ae57-5dba-a293-ba5f91fd7673 json: https://whiteintel.dev/api/public/dossier/25b5159c-ae57-5dba-a293-ba5f91fd7673 identifier: oo:GB-COH-12645831 jurisdiction: GB risk: Low source: WhiteIntel corporate-ownership graph --- # DARK BLUE THERAPEUTICS LTD **Type:** Company **Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb) **Identifier:** `oo:GB-COH-12645831` **Risk level:** Low **Canonical dossier:** https://whiteintel.dev/entity/25b5159c-ae57-5dba-a293-ba5f91fd7673 **Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/25b5159c-ae57-5dba-a293-ba5f91fd7673 ## Ownership & control ### Owners / controllers - **Dr Andrew James Mclean** (beneficial owner) — 100% — https://whiteintel.dev/entity/9229fa9a-e170-5782-af12-264f092dbb43 - **DARK BLUE THERAPEUTICS LTD** (beneficial owner) — 50% — https://whiteintel.dev/entity/25b5159c-ae57-5dba-a293-ba5f91fd7673 - **OXFORD SCIENCE ENTERPRISES PLC** (beneficial owner) — 50% — https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88 - **OXFORD SCIENCE ENTERPRISES PLC** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88 - **Dr Andrew James Mclean** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/793503d4-1ec9-4451-8c85-1d0df628b412 - **Oxford Science Enterprises Plc** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/7c529518-e807-4dea-bd40-7d3d1509c379 - **AMGEN UK HOLDINGS LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/3c82e9df-219e-44cc-899d-91d29d76f993 - **Bms Strategic Portfolio Investments Holdings, Inc.** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/68da0aa8-9872-4b89-9e3a-d8dc5ab24a25 - **Evotec International Gmbh** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/16559a95-59fe-444d-9301-279b213bbddc ### Holdings / subsidiaries - **SANDYMOUNT THERAPEUTICS LTD** (beneficial owner) — 100% — https://whiteintel.dev/entity/b7357cbd-21fc-55f5-b12d-64f6772e5267 - **SANDYMOUNT THERAPEUTICS LTD** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/b7357cbd-21fc-55f5-b12d-64f6772e5267 - **KLEIDOX THERAPEUTICS LTD** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/9720427b-ad58-4a1f-8fc7-d32e637919cf ### UBO chain (walk to the ultimate owner) A **10-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing. ## Company profile (live · UK Companies House) - **Company number:** `12645831` - **Status:** active - **Type:** ltd - **Incorporated:** 2020-06-04 - **Registered office:** Hayakawa Building, Edmund Halley Road, The Oxford Science Park, Oxford, OX4 4GB, United Kingdom - **SIC:** 72110 ### Officers - ABBERLEY, Russell James — director · British · appointed 2025-12-30 - PATEL, Binakumari Sanjay — director · British · appointed 2026-06-08 - SMITH, Emma — secretary · appointed 2023-03-09 · resigned 2025-12-30 - BROWN, Claire, Dr — director · British · appointed 2020-10-23 · resigned 2022-06-18 - CARMICHAEL, James, Dr — director · British · appointed 2020-07-24 · resigned 2025-12-30 - DIXON-CLEGG, Nicholas George — director · British · appointed 2022-06-18 · resigned 2024-05-16 - FOX, Justian Craig — director · British · appointed 2024-05-16 · resigned 2025-12-30 - HANKE, Thomas, Dr — director · German · appointed 2020-07-24 · resigned 2025-12-30 - MACKINNON, Alastair Graham — director · British · appointed 2022-08-08 · resigned 2025-12-30 - MCLEAN, Andrew James, Dr — director · British · appointed 2020-06-04 · resigned 2020-07-24 - MOSES, Edwin, Dr — director · British,Belgian · appointed 2025-03-17 · resigned 2025-12-30 - SCARLETT, Uciane — director · American · appointed 2020-07-24 · resigned 2020-08-21 - TAKENOSHITA, Takashi — director · Japanese · appointed 2020-07-24 · resigned 2022-06-18 - WALKER, Christopher Paul — director · British · appointed 2025-12-30 · resigned 2026-07-03 - WILKINSON, James Henry — director · British · appointed 2020-08-21 · resigned 2020-10-23 ### Beneficial owners (Persons with Significant Control) - [Amgen Uk Holdings Limited](https://whiteintel.dev/entity/3c82e9df-219e-44cc-899d-91d29d76f993) — 75–100% shares · corporate PSC · United Kingdom — since 2025-12-30 - Oxford Science Enterprises Plc — 25–50% shares · corporate PSC · England — ceased 2025-12-30 - Evotec International Gmbh — 25–50% shares · corporate PSC · Germany — ceased 2024-06-28 - [Bms Strategic Portfolio Investments Holdings, Inc.](https://whiteintel.dev/entity/68da0aa8-9872-4b89-9e3a-d8dc5ab24a25) — 25–50% shares · corporate PSC · United States — ceased 2025-12-30 - [Oxford Science Enterprises Plc](https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88) — 25–50% shares · corporate PSC · England — ceased 2022-10-17 - Dr Andrew James Mclean — 75–100% shares · individual PSC · United Kingdom — ceased 2020-07-24 ## Provenance - OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/12645831 - companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/12645831 ## Get the full, resolved dossier (agent-callable) The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent: ```bash npx -y @whiteintel/mcp-server # then: get_dossier · trace_ownership_path · check_offshore_exposure ``` Or unlock a one-off cited dossier for **DARK BLUE THERAPEUTICS LTD** — https://whiteintel.dev/entity/25b5159c-ae57-5dba-a293-ba5f91fd7673 · pricing https://whiteintel.dev/pricing. --- _This is the markdown-for-agents view of the WhiteIntel dossier for **DARK BLUE THERAPEUTICS LTD**. Human view: https://whiteintel.dev/entity/25b5159c-ae57-5dba-a293-ba5f91fd7673 · Structured JSON: https://whiteintel.dev/api/public/dossier/25b5159c-ae57-5dba-a293-ba5f91fd7673._ _Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._